LakeShore Biopharma Co., Ltd

NasdaqCM LSB

LakeShore Biopharma Co., Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2024

LakeShore Biopharma Co., Ltd Gross Profit is NA for the Trailing 12 Months (TTM) ending March 31, 2024. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • LakeShore Biopharma Co., Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.00.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
NasdaqCM: LSB

LakeShore Biopharma Co., Ltd

CEO Mr. Wang Xu
IPO Date Aug. 5, 2021
Location China
Headquarters Building No. 2
Employees 758
Sector Health Care
Industries
Biotechnology Pharmaceuticals Vaccines
Description

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.

StockViz Staff

January 15, 2025

Any question? Send us an email